1 / 66

Diagnostic Hematology: Disorders of Hemoglobin and Gammopathies

Diagnostic Hematology: Disorders of Hemoglobin and Gammopathies. Muhammad Shoaib Khan GM Centre - 1. a globin. b globin. b globin. a globin. Hemoglobin structure. Hgb A tetramer. Development period. a cluster - chromosome 16. Globin chain component. % of adult Hgb.

candid
Download Presentation

Diagnostic Hematology: Disorders of Hemoglobin and Gammopathies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Diagnostic Hematology: Disorders of Hemoglobin and Gammopathies Muhammad Shoaib Khan GM Centre - 1

  2. a globin b globin b globin a globin Hemoglobin structure Hgb A tetramer

  3. Development period a cluster - chromosome 16 Globin chain component % of adult Hgb Hgb name z a2 a1 Globin chain synthesis z2e2 Gower 1 z2g2 Portland Embryonic a2e2 Gower II a2g2 F Fetal <1% a2d2 A2 1.5-3.5% Adult a2b2 A >95% e Gg Ag d b b cluster - chromosome 11

  4. Thalassemia • Heterogenous group of disorders due to an imbalance of a and b globin chain synthesis • a thalssemia: a-globin chain production decreased • b thalassemia: b globin chain production decreased • The globin chains that are produced are normal • Quantitative deficiency: • bo thalassemia: No b-globin chain is made • b+ thalassemia: decreased b-globin chain is made • With 4 a genes and 2 b genes there is wide phenotypic variation

  5. Incidence of Thalassemia • ~100,000 patients with homozygous b-thalassemia world-wide • Found in Mediterranean countries, South Asia and Far East • Prevalence in the United Sates is increasing due to population migration

  6. Alpha Thalassemia • Inadequate production of alpha chains • Hemoglobin analysis normal; can be detected by a globin gene analysis • Absence of 1-2 alpha chains • Common • Asymptomatic • Does not require therapy • Absence of 3 alpha chains • Microcytic anemia (Hgb 7-10) • Splenomegaly • Absence of 4 alpha chains • Hydrops fetalis (non-viable)

  7. Laboratory Findings in Alpha Thalassemia  chains Hgb (g/dl) MCV (fl) RDW / Normal Normal Normal /- 12-14 75-85 Normal -/- or - -/ 11-13 70-75 - -/-  7-10 50-60 - -/- - - - -

  8. Minor (Trait) / + or / ° 10-13 Intermedia +/+ 7-10 Major +/° or °/° < 7 Beta Thalassemia Inadequate production of b chains Clinical Syndrome Genotype Hemoglobin (g/dl)

  9. Minor (Trait) / + or / ° 90-94 3.5-8 1-10 Intermedia +/+ 5-60 2-8 20-80% Major +/° 2-10 1-6 >85 °/° 0 1-6 >94 Beta Thalassemia - Hgb analysis Hemoglobin analysis: Increased levels of Hgb A2 and Hgb F Clinical Syndrome Genotype A A2 F

  10. Approach to Beta Thalassemia • Screening/counseling • RBC transfusion therapy • Agents to increase hemoglobin F (Hydroxyurea) • Bone marrow transplantation

  11. Clinical Presentations of Abnormal Hemoglobins • Sickling disorder • Thalassemia or microcytic anemia • Cyanosis • Erythrocytosis • Hemolytic anemia • Asymptomatic (screening or family study)

  12. Sickle Cell Disease • Inherited as autosomal recessive • Point mutation in beta globin (6 Glu Val) • Gene occurs in 8% of African-Americans

  13. Relative Frequency of Hemoglobin Variants

  14. Screening for Sickle Cell Traitand Disease • RBC lysate with concentrated phosphate buffer and sodium hydrosulfite • Incubate 10-20 min

  15. Hemoglobin Electrophoresis: Methodology • Separates hemoglobins on solid support media • Cellulose acetate (Alkaline gel) • Citrate agar (Acid gel) • Inexpensive and quickly prepared • Sharp resolution of major hemoglobin bands • Electrophoretic variability based on charge

  16. Hemoglobin electrophoresis

  17. Hemoglobin electrophoresis: Variants of sickle cell anemia

  18. Hemoglobin electrophoresis: Identification of abnormal hemoglobins

  19. High Pressure Liquid Chromatography (HPLC) • Separates hemoglobins by a cation exchange column • Resolution of various hemoglobins including Hgb F is excellent • Procedure can be automated leading to reliable interpretation • Hemoglobin fractions can be quantified

  20. A0 A1C HPLC: Normal Adult Hemoglobin

  21. HPLC: Sickle cell trait

  22. HPLC: Sickle cell anemia (Hgb SS) Hb F A 2

  23. HPLC: Hgb SC disease

  24. Monoclonal Gammopathies • Laboratory evaluation of gammopathies • Diseases associated with gammopathies • Common clinical syndromes

  25. Clinical indications for the evaluation of immunoglobulins • Normochromic normocytic anemia • Nephrotic syndrome in a non-diabetic patient • Osteolytic lesions • Lymphadenopathy • Non-ischemic heart failure • Elevated total serum protein • Hypercalcemia

  26. Free light chains • Have been detected in urine for >50 years * • Polyclonal antibody against free LC • Purified so no cross-reactivity and does not bind to intact immunoglobulin • Bound to latex beads - detected by a variety of techniques (turbidity) * Korngold and Lapiri Cancer: (1956) 9:262-272

  27. Representative sensitivity levels Kappa Lambda SPEP 500-2000 mg/L 500-2000mg/L IFE 150-500 mg/L 150-500 mg/L Free light chains 1.5 mg/L 3.0 mg/L

  28. l FLC (mg/L) k FLC (mg/L) Comparison of FLC measurements in serum and urine in healthy individuals

  29. l FLC (mg/L) Serum free light chains Composite Figure of serum free light chain concentrations in various diseases

  30. Potential uses of serum free light chains • Sensitive marker for diagnosing monoclonal lymphoproliferative diseases • k/l ratio may be a prognostic marker for MGUS • Useful marker in non-secretory myeloma or patients with only Bence-Jones proteinuria • Marker to follow disease

  31. Lymphoproliferative Disorders Commonly Associated with a Monoclonal Gammopathy • Monoclonal gammopathy of undetermined significance (MGUS) • Multiple myeloma • Waldenstroms macroglobulinemia • Amyloidosis

  32. Monoclonal Gammopathies of Undetermined Significance (MGUS) • Commonly found on serum protein electrophoresis • Occurs in ~2% of persons > 50 years of age • Characteristics • Low serum monoclonal protein concentration (<3 g/dl) • Less than 5% plasma cells in bone marrow • Little or no monoclonal protein in urine • Absence of lytic bone lesions • No anemia, hypercalcemia, or renal insufficiency

  33. “Benign MonoclonalGammopathy” Course of MGUS in 241 Patients Am J Med 1978; 64:814-26 N Engl J Med 2002;346:564-9 (Updated)

  34. Patterns of Monoclonal Protein Increase Multiple myeloma Pattern No. patients (%) Stable with sudden increase 19 (25%) Stable with gradual increase 9 (12%) Gradual increase 9 (12%) Sudden increase 11 (15%) Stable 10 (13%) Indeterminate 17 (23%) N Engl J Med 2002:346; 564-9

  35. Summary:(MGUS) • Monoclonal proteins rarely disappear spontaneously (<5%) • MGUS is a risk factor for multiple myeloma and related disorders • Risk of progression to multiple myeloma or related disorders is increased with higher initial monoclonal protein levels • Risk of progression is ~1 % per year

  36. Multiple Myeloma: Incidence and Etiology • 13,000 cases/year in USA • Median age - 65 yrs. • Incidence in African-Americans is two-fold other ethnic groups • Familiar clusters are rare • Environmental/occupational exposures have been implicated

  37. Multiple Myeloma: Clinical Manifestations • Bone pain/skeletal involvement • Fatigue/anemia • Renal insufficiency • Hypercalcemia • Neurologic symptoms • Infections

  38. Laboratory evaluation • CBC with peripheral smear • Chemistry panel (Include calcium and creatinine) • SPEP/UPEP (immunofixation electrophoresis) • Urinalysis/24 hr urine for protein • Bone marrow exam • Skeletal survey • LDH and b2-microglobulin • Serum viscosity

  39. Peripheral smear: Plasma cell

  40. Bone marrow aspirate: Plasma cell infiltrate

  41. Diagnostic Criteria for Multiple Myeloma • Major criteria • I. Bone marrow plasmacytosis > 30% • II. Histologic diagnosis of plasmacytoma • III. Serum paraprotein IgG > 3.5 g/dl or IgA > 2.0 g/dl • Minor criteria • a. Bone marrow plasmacytosis 10-30% • b. Serum paraprotein less than major criteria • c. Osteolytic lesion • d. Hypogammaglobulinemia • One major criteria and one minor criteria • Minor criteria a + b and one other

  42. Waldenstroms MacroglobulinemiaIncidence and clinical features • 1,500 cases/year in USA • Median age -, 63 yrs • Presenting symptoms • Weakness and fatigue 44% • Hemorrhagic manifestations 44% • Weight loss 23% • Neurologic symptoms 11% • Visual disturbances 8% • Raynauds phenomenon 3%

  43. Waldenstroms Macroglobulinemia:Clinical Features • Tumor infiltration • Bone marrow 90% • Splenomegaly 38% • Lymphadenopathy 30% • Circulating IgM • Hyperviscosity syndrome 15-20% • Cryoglobulinemia 5-15% • Cold agglutinin disease 5-10% • Bleeding disorders 10% • Tissue IgM • Neuropathy 10-20%

More Related